Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is listed today as Recursion Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2020 | $246 M | No. 5 | $50 to $250 million | equity | SEC | |
| Feb 2019 | $122 M | No. 4 | $50 to $250 million | equity | SEC | |
| Sep 2017 | $56 M | No. 3 | $50 to $250 million | equity | SEC | |
| Sep 2016 | $15 M | No. 2 | $10 to $50 million | equity | SEC | |
| Sep 2016 | $4 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Recursion Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Operating revenue $74.26 million (99%), Grant revenue $420,000 (1%).
Annual report (SEC XBRL) · Dec 2025
Recursion Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).
SEC Form D · Nov 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2020
Products and services#
No products or services of Recursion Pharmaceuticals, Inc. are on record.
Investors#
15 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Blake Borgeson | Person | not stated | not stated | Held Series A and A-1 preferred stock, director (Form 3, 2021) | SEC Form 3 |
| Christopher Gibson | Person | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Data Collective IV GP, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Data Collective IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| DCVC Opportunity Fund II GP, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| DCVC Opportunity Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Dcvc V GP, LLC | Other | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Dcvc V, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Lux Co-Invest Opportunities, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Lux Co-Invest Partners, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Lux Venture Partners IV, LLC | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Lux Ventures IV, L.P. | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Mamoura Diversified Global Holding PJSC | Other | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Michael Secora | Person | not stated | not stated | Held Series D preferred stock (Form 3, 2021) | SEC Form 3 |
| Mubadala Investment Co PJSC | Fund or asset manager | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 49 investors.
Largest shareholders today
Institutions holding Recursion Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$221 M8.59%
- ARK Investment Management LLC$185 M7.18%
- Vanguard Portfolio Management LLC$148 M5.75%
- State Street Corp$124 M4.82%
- Vanguard Capital Management LLC$95 M3.69%
- Baillie Gifford & Co$75 M2.92%
- Geode Capital Management, LLC$57 M2.23%
- Softbank Group Corp.$56 M2.19%
- FMR LLC$47 M1.84%
- UBS Group AG$35 M1.35%
- MIC Capital Management UK LLP$34 M1.33%
- Two Sigma Investments, LP$33 M1.28%
- Morgan Stanley$26 M1.00%
- Data Collective IV GP, LLC$25 M0.95%
- Price T Rowe Associates Inc /MD/$24 M0.92%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christopher C. Gibson | Executive officer | Nov 2020 |
| Michael Martin Secora | Executive officer | Nov 2020 |
| Blake C. Borgeson | Executive officer | Oct 2017 |
| John Perry Pereira | Executive officer | Oct 2017 |
| Dean Y. Li | Executive officer | Dec 2016 |
| Dean C. Li | Dr. Li ceased to be a director upon conversion of the LLC to a corporation. | Sep 2016 |
| Blake C. Borgeson | Director | Nov 2020 |
| Christopher C. Gibson | Director | Nov 2020 |
| Dean C. Li | Director | Nov 2020 |
| R. Martin Chavez | Director | Nov 2020 |
| Robert C. Hershberg | Director | Nov 2020 |
| Terry-Ann C. Burrell | Director | Nov 2020 |
| Zachary C. Bogue | Director | Nov 2020 |
| Zavain C. Dar | Director | Nov 2020 |
| H. Perry Fell | Director | Oct 2017 |
| Zachary Perry Bogue | Director | Oct 2017 |
| Zavain Perry Dar | Director | Oct 2017 |
| Reid Perry Hutchins | Director | Dec 2016 |
| Dean Y. Li | Dr. Li ceased to be a director upon conversion of the LLC to a corporation. | Sep 2016 |
| Christopher C. Gibson | Promoter | Nov 2020 |
| Michael Martin Secora | Promoter | Nov 2020 |
| Blake C. Borgeson | Promoter | Oct 2017 |
| Dean Y. Li | Promoter | Dec 2016 |
| Dean C. Li | Dr. Li ceased to be a director upon conversion of the LLC to a corporation. | Sep 2016 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.